nuclear receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-10 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
=== Reuse of intermodal steel shipping containers === The widespread availability and relative cheapness of used intermodal shipping containers meant that architects began to consider them as an alternative to traditional building materials. Used shipping containers have been converted for use in housing, and as retail and office spaces. Examples of its use include the Cité A Docks student housing project in Le Havre, France; the Wenckehof container village in Amsterdam; the portable Puma City store in US cities; the food and retail Boxpark in London; the Dordoy Bazaar in Bishkek, Kyrgyzstan; the temporary mall Re:START in Christchurch, New Zealand built after the 2011 Christchurch earthquake, and as intensive-care units in temporary hospitals during the COVID-19 pandemic. The Smoky Park Supper Club in Asheville, North Carolina, opened in 2015, was constructed from 19 containers and is considered " "America's largest recycled shipping container restaurant." It has however been pointed out there are problems with recycling shipping containers, that it may not be as ecologically friendly or cheap an option as it might appear. The containers may be coated with harmful chemicals such as chromate, phosphorus, and lead-based paints, while its wooden floors may be treated with toxic insecticides, and some cost and effort are involved in modifying containers to make them habitable. Others have noted various issues such as space constraint, insulation, and structural weakness if too much steel is cut out of the containers.
Donald Trump began his second term with another historically low job approval rating, only improving on his lowest-ever rating (occurring in his first term) by three percentage points. President Trump began his first term at 45% job approval, and his second with 47%. According to Gallup, "Trump remains the only elected president with sub-50% initial approval ratings". In a CBS News/YouGov poll conducted from February 5–7, 2025, Trump reached a career high poll rating of 53%. According to ABC News, Trump's approval rating at the end of his first 100 days in office was 39%, even lower than his already low 42% approval rating at the end of his first 100 days of his first presidency and the worst of any president's approval ratings after their 100 days in 80 years. By July 2025, Gallup found Trump's approval rating reached the lowest for his second term at 37%, largely driven by declining support from independents, and in August, multiple surveys revealed record or near-record low job approval ratings, which Gallup found to be lower than any modern president. As was the case during Trump's first term, the president's approval ratings have remained remarkably stable. His ratings are also very polarized, often with more Republicans than Democrats approving of his leadership. In May 2026, a Washington Post–ABC News–Ipsos poll reported declining approval of Trump's leadership, with respondents expressing dissatisfaction over issues including the Iran war and economic policy.
== Organization and leadership == The National Institutes of Health (NIH) is composed of 27 Institutes and Centers, most of which include research programs led by a Scientific Director and conducted by federal researchers and their trainees at one of several NIH campus locations. Collectively, these research programs encompass the Intramural Research Program (IRP). The IRP includes the United States National Library of Medicine, an international resource for researchers, and the NIH Clinical Center, the world's largest clinical research hospital. Intramural researchers are affiliated with individual Laboratories, Branches or Centers, which are typically organized around common thematic research goals and approaches, much like a department or center at an academic institution. Within these larger structures, Principal Investigators run Sections or Units devoted to their independent research goals. Core facilities, supported by staff scientists and clinicians, are among the shared resources available to IRP researchers. Scientific interests are not bound by the organizational structure. There exists a full spectrum of scientific interest groups (called SIGs) that brings researchers from different Institutes and Centers together around common areas of scientific interest where ideas can be shared and collaborations initiated. In addition, institutes come together to work cooperatively on major initiatives focused on unraveling the complexities of disease.
=== Thomson Medal Award (since 1985) === 2024 Jennifer S. Brodbelt 2022 Vicki Wysocki and Lidia Gall 2020 Alison E. Ashcroft 2014 Carol V. Robinson 2009 Catherine E. Costello and Catherine. C. Fenselau
Sources: en.wikipedia.org
A permanent routine of exercise, eating healthily, and, during periods of being overweight, consuming the same number or fewer calories than used will prevent and help fight obesity. A single pound of fat yields approximately 3500 calories of energy (32 000 kJ energy per kilogram of fat), and weight loss is achieved by reducing energy intake, or increasing energy expenditure, thus achieving a negative balance. Adjunctive therapies which may be prescribed by a physician are orlistat or sibutramine, although the latter has been associated with increased cardiovascular events and strokes and has been withdrawn from the market in the US, the UK, the EU, Australia, Canada, Hong Kong, and Thailand. A 2006 study published in the International Journal of Sport Nutrition and Exercise Metabolism suggests that combining cardiovascular (aerobic) exercise with resistance training is more effective than cardiovascular training alone in getting rid of abdominal fat. An additional benefit to exercising is that it reduces stress and insulin levels, which reduce the presence of cortisol, a hormone that leads to more belly fat deposits and leptin resistance. Age-related increases in central adiposity are strongly linked to a progressive decline in basal metabolic rate and loss of lean body mass in adult males. To effectively reduce visceral fat and maintain metabolic health, structured physical activity combining both aerobic and resistance training is recommended.
Treatment may include dietary changes, iron supplements, and dealing with underlying causes, for example, medical treatment for parasites or surgery for ulcers. Supplementation with vitamin C may be recommended due to its potential to aid iron absorption. Severe cases may be treated with blood transfusions or iron infusions. Iron-deficiency anemia affected about 1.48 billion people in 2015. A lack of dietary iron is estimated to cause approximately half of all anemia cases globally. Women and young children are most commonly affected. In 2015, anemia due to iron deficiency resulted in about 54,000 deaths – down from 213,000 deaths in 1990.
The first woman, Valentina Tereshkova, was launched into space on Vostok 6 on June 16, 1963, as (possibly) a medical experiment. She was the only one to fly of a small group of female parachutist factory workers (unlike the male cosmonauts who were military test pilots), chosen by the head of cosmonaut training because he read a tabloid article about the "Mercury 13" group of women wanting to become astronauts, and got the mistaken idea that NASA was actually entertaining this. Five months after her flight, Tereshkova married Vostok 3 cosmonaut Andriyan Nikolayev, and they had a daughter.
Despite the UN arms embargo on Bosnia, the ISI under General Javed Nasir airlifted anti-tank weapons and missiles to Bosnian mujahideen, shifting the tide in favour of Bosnian Muslims. ISI, under Nasir's leadership, supported Chinese Muslims in Xinjiang, rebel groups in the Philippines, and religious groups in Central Asia. Since 2001, the Pakistan military has been engaged in counterinsurgency and internal security operations in the Khyber Pakhtunkhwa province, primarily targeting Tehrik-e-Taliban Pakistan and associated militant groups. Major military operations conducted during this period include Operation Enduring Freedom, Operation al-Mizan, Operation Zalzala, Operation Sherdil, Operation Rah-e-Haq, Operation Rah-e-Rast, and Operation Rah-e-Nijat.
Before the second half of the nineteenth century, the remarkable potency and specificity of the actions of drugs such as morphine, quinine, and digitalis were explained vaguely and with reference to extraordinary chemical powers and affinities to certain organs or tissues. The first pharmacology department was set up by Rudolf Buchheim in 1847, at the University of Tartu, in recognition of the need to understand how therapeutic drugs and poisons produced their effects. Subsequently, the first pharmacology department in England was set up in 1905 at University College London. Pharmacology developed in the 19th century as a biomedical science that applied the principles of scientific experimentation to therapeutic contexts. The advancement of research techniques propelled pharmacological research and understanding. The development of the organ bath preparation, where tissue samples are connected to recording devices, such as a myograph, and physiological responses are recorded after drug application, allowed analysis of drugs' effects on tissues. The development of the ligand binding assay in 1945 allowed quantification of the binding affinity of drugs at chemical targets. Modern pharmacologists use techniques from genetics, molecular biology, biochemistry, and other advanced tools to transform information about molecular mechanisms and targets into therapies directed against disease, defects or pathogens, and create methods for preventive care, diagnostics, and ultimately personalized medicine.
Sources: en.wikipedia.org
radians) electric sector, a drift length which is followed by a 90° magnetic sector of opposite curvature direction. The entry of the ions sorted primarily by charge into the magnetic field produces an energy focussing effect and much higher transmission than a standard energy filter. This geometry is often used in applications with a high energy spread in the ions produced where sensitivity is nonetheless required, such as spark source mass spectrometry (SSMS) and secondary ion mass spectrometry (SIMS). The advantage of this geometry over the Nier–Johnson geometry is that the ions of different masses are all focused onto the same flat plane. This allows the use of a photographic plate or other flat detector array.
Furthermore, leveraging strategic technical collaborations with global big tech — such as OpenAI, Microsoft, Google Cloud, AWS, Cohere, Anthropic, and Palantir—the company actively deploys enterprise operations encompassing generative AI, data analytics, AI agents, and cloud-based AX business. RX (Robotic Transformation): LG CNS accelerates robotic commercialization through its 'Full-Stack RX Services', which strategically combine industry-specific Robot Foundation Models (RFM), hardware, and platforms. Through 'PhysicalWorks', the first integrated robot learning and operations platform developed by a South Korean firm, the company trains robots for real-world industrial tasks, manages task and workflow allocation, and provides central orchestration to monitor and operate heterogeneous robot fleets under a single platform. The company is also collaborating with U.S.-based robotics innovators, such as 'Dexmate' and the robotic brain development firm 'Skild AI,' to co-develop advanced physical AI systems. Cloud & AI Data Centers: The company delivers cloud transformation consulting, integration, and Managed Service Provider (MSP) services, along with data center infrastructure development. LG CNS became the first South Korean firm to secure an overseas AI data center construction project, with plans to complete a hyper-scale AI data center in Jakarta, Indonesia, by the end of 2026. In the cloud infrastructure sector, it maintains strategic partnerships with AWS, Microsoft Azure, and Google Cloud.
=== Microbiota === Probiotic bacteria found in kefir products include Lactobacillus acidophilus, Bifidobacterium bifidum, Streptococcus thermophilus, Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus helveticus, Lactobacillus kefiranofaciens, Lactococcus lactis, and Leuconostoc species. Lactobacilli in kefir may exist in concentrations varying from approximately 1 million to 1 billion colony-forming units per milliliter, and are the bacteria responsible for the synthesis of the polysaccharide kefiran. In addition to bacteria, kefir often contains strains of yeast that can metabolize lactose, such as Kluyveromyces marxianus, Kluyveromyces lactis, and Saccharomyces fragilis, as well as strains of yeast that do not metabolize lactose, including Saccharomyces cerevisiae, Torulaspora delbrueckii, and Kazachstania unispora. The nutritional significance of these strains is not currently known with certainty.
The delegation argued that the annexation was a violation of prior agreements between Moshoeshoe and Wodehouse, while disarmament was unnecessary since the Basuto remained loyal to the Cape. The delegation was not allowed to present its case in the parliament. Petitions from the Basuto and their sympathizers from among the Paris Evangelical Society missionaries followed, all of which failed to produce a favorable result. Letsie I, now old and in declining health, was unwilling to lead an armed revolt, believing it to be futile. Cape Governor Sir Henry Bartle Frere became impatient at the deliberations and ordered Letsie I to enact disarmament immediately, even before the Basuto delegation had returned from Cape Town. Few Basuto complied with the order and handed over their arms. This catalyzed the Cape Parliament to vote in favor of disarmament. The delegation announced their failure to prevent the enactment of the Peace Preservation Act at a pitso convened on 3 July. The heir to the Basuto throne, Lerotholi, spoke against disarmament, while Letsie's brother chief Masopha and his nephew chief Joel Molapo openly challenged the order and advocated for armed resistance. Masopha began to fortify the stronghold of Thaba Bosiu, while the supporters of the rebel chiefs began ignoring orders from the local magistrates. White traders abandoned Basutoland, and Basuto loyalists fled to the magistracies for protection as armed bands roamed freely in the region.
==== Positive criminology and positive victimology ==== Positive criminology and positive victimology are conceptual approaches, developed by the Israeli criminologist Natti Ronel and his research team, that follow principles of positive psychology and apply them into the fields of criminology and victimology, respectively. Positive criminology and victimology both place an emphasis on social inclusion and on unifying and integrating forces at individual, group, social and spiritual levels that are associated with the limiting of crime and recovery from victimization. In traditional approaches, the study of crime, violence and related behaviors emphasizes the negative aspects in people's lives that are associated with deviance, criminality and victimization. A common understanding is that human relationships are affected more by destructive encounters than by constructive or positive ones. Positive criminology and victimology argue that a different approach is viable, based on three dimensions – social integration, emotional healing and spirituality – that constitute positive direction indicators.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.